Ankylosing Spondylitis (Bekhterev’s Disease) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline Review, H1 2017’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)

– The report reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ankylosing Spondylitis (Bekhterev's Disease) therapeutics and enlists all their major and minor projects

– The report assesses Ankylosing Spondylitis (Bekhterev's Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amgen Inc

Biocad

Biocon Ltd

Bionovis SA

Celgene Corp

Coherus BioSciences Inc

Galapagos NV

Genor BioPharma Co Ltd

Immunwork Inc

Innovent Biologics Inc

Johnson & Johnson

Merck KGaA

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Novartis AG

Oncobiologics Inc

Protalix BioTherapeutics Inc

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Shanghai Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

UCB SA

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ankylosing Spondylitis (Bekhterev's Disease) - Overview 8

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 13

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 24

AbbVie Inc 24

Adello Biologics LLC 24

Allergan Plc 25

Alteogen Inc 25

Amgen Inc 26

Biocad 26

Biocon Ltd 27

Bionovis SA 27

Celgene Corp 28

Coherus BioSciences Inc 28

Galapagos NV 29

Genor BioPharma Co Ltd 29

Immunwork Inc 30

Innovent Biologics Inc 30

Johnson & Johnson 31

Merck KGaA 31

Momenta Pharmaceuticals Inc 32

Mycenax Biotech Inc 32

Novartis AG 33

Oncobiologics Inc 33

Protalix BioTherapeutics Inc 34

Reliance Life Sciences Pvt Ltd 34

Sandoz International GmbH 35

Shanghai Pharmaceutical Co Ltd 35

Sun Pharma Advanced Research Company Ltd 36

UCB SA 36

Xbrane Biopharma AB 37

Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles 38

adalimumab biosimilar - Drug Profile 38

adalimumab biosimilar - Drug Profile 40

adalimumab biosimilar - Drug Profile 41

adalimumab biosimilar - Drug Profile 42

adalimumab biosimilar - Drug Profile 43

adalimumab biosimilar - Drug Profile 44

adalimumab biosimilar - Drug Profile 45

adalimumab biosimilar - Drug Profile 47

adalimumab biosimilar - Drug Profile 50

adalimumab biosimilar - Drug Profile 51

adalimumab biosimilar - Drug Profile 52

adalimumab biosimilar - Drug Profile 54

adalimumab biosimilar - Drug Profile 55

adalimumab biosimilar - Drug Profile 56

apremilast - Drug Profile 57

BAT-1406 - Drug Profile 68

BCD-085 - Drug Profile 69

bimekizumab - Drug Profile 70

certolizumab pegol biosimilar - Drug Profile 72

DNX-114 - Drug Profile 73

DNX-514 - Drug Profile 74

etanercept biosimilar - Drug Profile 75

etanercept biosimilar - Drug Profile 77

etanercept biosimilar - Drug Profile 79

etanercept biosimilar - Drug Profile 80

etanercept biosimilar - Drug Profile 81

etanercept biosimilar - Drug Profile 82

etanercept biosimilar - Drug Profile 86

etanercept biosimilar - Drug Profile 87

etanercept biosimilar - Drug Profile 90

filgotinib - Drug Profile 91

golimumab - Drug Profile 103

golimumab biosimilar - Drug Profile 112

golimumab biosimilar - Drug Profile 113

HEISCO-III-002 - Drug Profile 114

infliximab biosimilar - Drug Profile 115

infliximab biosimilar - Drug Profile 116

infliximab biosimilar - Drug Profile 117

infliximab biosimilar - Drug Profile 120

infliximab biosimilar - Drug Profile 121

infliximab biosimilar - Drug Profile 122

infliximab biosimilar - Drug Profile 123

risankizumab - Drug Profile 124

secukinumab - Drug Profile 128

TE-2122 - Drug Profile 141

TE-2158 - Drug Profile 142

thalidomide - Drug Profile 143

tildrakizumab - Drug Profile 144

upadacitinib tartrate - Drug Profile 147

VTP-43742 - Drug Profile 151

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 154

Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 156

Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 157

Featured News & Press Releases 157

Appendix 169

Methodology 169

Coverage 169

Secondary Research 169

Primary Research 169

Expert Panel Validation 169

Contact Us 169

Disclaimer 170

List of Tables

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by AbbVie Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Adello Biologics LLC, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Allergan Plc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Alteogen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Amgen Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocad, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Biocon Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Bionovis SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Celgene Corp, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Coherus BioSciences Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Galapagos NV, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Genor BioPharma Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Immunwork Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Innovent Biologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Johnson & Johnson, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Merck KGaA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Mycenax Biotech Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Novartis AG, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Oncobiologics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Protalix BioTherapeutics Inc, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sandoz International GmbH, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by UCB SA, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline by Xbrane Biopharma AB, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Ankylosing Spondylitis (Bekhterev's Disease) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports